Thryve, providers of high quality microbiotics and microbiome testing, announced today it has secured $1.4 million in funding. Participating investment firms include PivotNorth Capital, Unilever Ventures, Darling Ventures, Candela Paramount, Abstract Ventures and Joyance Partners. […]
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced that Aoife Brennan, M.B., B.Ch., has accepted the position of Interim President and Chief Executive […]
Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo”) today announced the pricing of its initial public offering of 5,312,500 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. In […]
Lodo Therapeutics Corporation, a drug discovery and development company focused on identifying and producing unique, bioactive natural products directly from the microbial DNA sequence information contained in soil, today announced that it has formed a […]
Adare Pharmaceuticals, Inc., today announced changes to its Leadership Team to support the next phase of its growth strategy. Since its creation in 2015, the Company has been committed to becoming a global specialty pharmaceutical […]
UAS Laboratories LLC (Wausau, Wisconsin, USA), is celebrating a significant milestone with the opening of their new fermentation facility, located in Madison, Wisconsin, USA. This expansion is the result of a 60-million-dollar investment made to […]
Azitra Inc. today announced that it has secured $2.15 million in convertible debt financing to support advancement of the company’s pipeline of dermatology and skin care products. The financing was led by new investor Connecticut […]
Eagle Genomics has appointed Executive Chairman Anthony Finbow to the post of Chief Executive, with founder Abel Ureta-Vidal moving to become Chief Product Officer. The change in management structure marks a new phase for Eagle […]
A-Mansia Biotech S.A. (A-Mansia), the microbiome company focused on developing products based on the unique properties of the Akkermansia muciniphila (A. muciniphila) bacterium, today announces a €13 million first close of its Series A financing, […]
Comments from the Managing Director: “Sales for the first quarter of 2018 amounted to SEK 157 million, which was an increase of 13% (excluding foreign exchange effects) compared to the corresponding period last year. Revenue […]
ReviveMed Inc., today announced it has closed an oversubscribed seed round of $1.5 million to advance its artificial intelligence (AI)-driven platform that unlocks the value of metabolomics data for drug discovery and development. Rivas Capital […]